Close Menu

Editor's Pick

The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.

The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.

The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.

The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.

In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases. 

The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.

The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.

Pages